The relationship between the androgen receptor CAG repeat polymorphism length and the response to intermittent androgen suppression therapy for advanced prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 8, Issue 2, 2005, Pages 179-183

  Klotz, Laurence ^a   Correia, A ^a   Zhang, W ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Androgen deprivation therapy; CAG repeats

Indexed keywords

ADENINE; ANDROGEN RECEPTOR; ANTIANDROGEN; BUSERELIN; CYTOSINE; GONADORELIN; GUANINE; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG RESPONSE; HORMONE INHIBITION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TRINUCLEOTIDE REPEAT; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTION AND FORECASTING; PROSTATE TUMOR; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TREATMENT OUTCOME; TRINUCLEOTIDE REPEATS;

EID: 23944454946     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500792     Document Type: Article

References (19)

1. Klotz LH et al. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986; 58: 2546-2560.
2. Pether M, Goldenberg SL. Intermittent androgen suppression. Br J Urol Int 2004; 93: 258-261.
3. Edwards A et al. Genetic variation at five trimeric and tetrameric tandem repeat risk. Cancer Res 1997; 57: 1194-1198.
4. Chamberlain N, Driver E, Meisfeld R. The length and location of the CAG trinucleotide repeats in the androgen receptor of N terminal domain affect on transactivation function. Nuclec Acid Res 1994; 22: 3181-3186.
5. Nelson KA, Witte JS. Androgen receptor CAG repeats and prostate cancer. Am J Epidemiol 2002; 155: 883-890.
6. Hakimi J, Rondinelli R, Schoenberg M, Banack E. Androgen receptor gene structure and function in prostate cancer. World J Urol 1996; 14: 329-337.
7. Edwards KJ et al. The CAG trinucleotide repeat length in the androgen receptor does not predict the early onset of prostate cancer. Br J Urol Int 2002; 90: 573-578.
8. Irvine R, Yu M, Ross R, Coetzee G. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995; 55: 1937-1940.
9. Giovanucci E et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 1997; 94: 3320-3323.
10. Bratt O et al. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br J Cancer 1999; 81: 672-676.
11. Hardy DO et al. Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J Clin Endocrinol Metab 1996; 81: 4400-4405.
12. Ingles SA et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997; 89: 166-170.
13. Hakimi JM et al. Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. Clin Cancer Res 1997; 3: 1599-1608.
14. Stanford JL et al. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 1997; 57: 1194-1198.
15. Correa-Cerro L et al. (CAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population. Eur J Hum Genet 1999; 7: 357-362.
16. Edwards SM et al. Androgen receptor polymorphisms: Association with prostate cancer risk, relapse, and overall survival. Int J Cancer 1999; 84: 458-465.
17. Nam R et al. Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression. J Urol 2000; 164: 567-572.
18. Suzuki H et al. CAG polymorphic repeat lengths in androgen receptor gene among Japanese prostate cancer patients: Potential predictor of prognosis after endocrine therapy. Prostate 2002; 51: 219-224.
19. Pinker-Shaeffer C et al. Molecular and cellular changes associated with the acquisition of metastatic ability by prostate cancer cells. Prostate 1994; 25: 249-265.